How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks?

How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks?

Wed, September 2, 2026 at 4:23 PM GMT+3 2 min read

• BSX -2.94%

With a market cap of $69.7 billion, Boston Scientific Corporation (BSX) is a global medical technology leader focused on developing innovative solutions that improve patient health and transform lives. The company offers a broad portfolio of high-performance devices and therapies designed to address unmet medical needs while helping reduce healthcare costs.

Companies valued at more than $10 billion are generally considered "large-cap" stocks, and Boston Scientific fits this criterion perfectly. Its technologies support physicians in diagnosing and treating complex cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions.

More News from Barchart

Shares of the Marlborough, Massachusetts-based company have pulled back 56.1% from its 52-week high of $109.50. Boston Scientific's shares have risen marginally over the past three months, underperforming the State Street SPDR S&P Health Care Equipment ETF's (XHE) 19.3% return over the same time frame.

BSX stock is down 49.6% on a YTD basis, lagging behind XHE's 6.5% gain. Moreover, shares of the medical device manufacturer have decreased 54.4% over the past 52 weeks, compared to XHE's 14.4% increase over the same time frame.

Despite recent fluctuations, the stock has been trading below its 50-day and 200-day moving averages since last year.

Despite reporting better-than-expected Q2 2026 adjusted EPS of $0.86, Boston Scientific shares fell marginally on Jul. 29 after the company cut its 2026 adjusted EPS outlook to $3.28 - $3.32, below the analyst estimate, citing weaker Watchman demand and tougher U.S. electrophysiology competition. Watchman procedure growth slowed as physicians increasingly combined the implant with other cardiac treatments and changing clinical evidence disrupted referrals, while EP competition caused market-share losses expected to persist into 2027.

In comparison, rival Stryker Corporation (SYK) has shown a less pronounced decline than BSX stock. SYK stock has dropped 9.5% on a YTD basis and 18.5% over the past 52 weeks.

Due to the stock's weak performance over the past year, analysts remain strongly optimistic on BSX. The stock has a consensus rating of "Strong Buy" from the 30 analysts covering it, and the mean price target of $61.04 is a premium of nearly 27% to current levels.

On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com